Published Online: March 31, 2014. doi:10.1001/jama.2014.3584.
Study concept and design: Kozuma, Morimoto, Kimura.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Natsuaki, Kimura.
Critical revision of the manuscript for important intellectual content: Kozuma, Morimoto, Shiomi, Kimura.
Statistical analysis: Natsuaki, Morimoto, Shiomi, Kimura.
Obtained funding: Kimura.
Administrative, technical, or material support: Kozuma, Morimoto, Kimura.
Study supervision: Kozuma, Kimura.
Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Drs Kozuma and Kimura reported being advisory board members of Terumo Japan and Abbott Vascular Japan. Dr Kozuma also reported receiving fees for giving lectures for Abbott Vascular Japan, Terumo, Boston Scientific Japan, Nipro, Medtronic Japan, and Orbus Neich; serving as a consultant to Terumo and Zeon Medical; and being an advisory board member for Nipro. No other disclosures were reported.
Funding/Support: The NOBORI Biolimus-Eluting vs XIENCE/PROMUS Everolimus-Eluting Stent Trial (NEXT) trial was funded by Terumo Japan.
Role of the Sponsor: Terumo Japan had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We appreciate the effort of the members of the cardiac catheterization laboratory and clinical research coordinators in the participating centers.
Trial Registration clinicaltrials.gov Identifier: NCT01303640